Evidence map›Paper›PMID 42426738›Full record

ArticleWorld journal of surgical oncology2026

CDK4/6 inhibitor combined with endocrine therapy: a real-world evaluation of efficacy and safety in HR+/HER2- advanced breast cancer.

Rui Wang, Yuying Wang, Yaling Zeng, Xihui Tu, Di Lu, Purong Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rui WangDepartment of Thyroid and Breast Surgery, Mianyang 404 Hospital, Mianyang, Sichuan, 621000, China.
Yuying WangDepartment of Health Management, Qionglai Medical Center Hospital, Qionglai, Sichuan, China.
Yaling ZengSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xihui TuCollege of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, 637000, China.
Di LuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Purong ZhangDepartment of Breast Surgery, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610000, China. zprrong123321@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) constitutes the standard treatment for Hormone receptor-positive (HR+)/Human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). It is essential to evaluate the efficacy and safety profiles of CDK4/6i in Chinese patients with HR+/HER2- ABC, in order to provide a theoretical foundation for developing precision-based therapeutic strategies.

methodsClinical data of patients with ABC treated with CDK4/6i combined with ET between April 2021 and April 2024 at the Department of Breast Oncology, Sichuan Cancer Hospital, were retrospectively collected. Clinicopathological characteristics and prognostic outcomes were analyzed to evaluate the efficacy and safety of CDK4/6i-based regimens, and then we explored factors associated with progression-free survival (PFS). The secondary endpoints incorporate overall survival (OS), objective response rate (ORR) and clinical benefit rate (CBR).

resultsA total of 124 patients were enrolled, with a median follow-up period of 23.0 months. The median PFS (mPFS) was 20.0 months, while the median OS (mOS) was not reached. Patients without measurable target lesions were excluded, and a total of 90 patients were included for further analysis. The ORR was 46.7% (42/90), and the CBR was 53.3% (48/90). Cox multivariate regression analysis identified Ki-67<20%, Age-adjusted Charlson Comorbidity Index (aCCI)<10, line of CDK4/6i ≤ 2, and sensitivity or acquired resistance to ET as independent predictors of PFS. Leukopenia (83.1%) was the most common adverse event (AE), with 75.8% of these cases classified as grade 1-2.

conclusionThis real-world (RWD) study in China has further confirmed the efficacy and safety in HR+/HER2- ABC. These findings provide further evidence for clinically identifying optimal patient population likely to derive superior benefits from CDK4/6i combination regimens.

Indexed as

Antineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedPrognosisProgression-Free SurvivalReceptors, EstrogenAntineoplastic Agents, HormonalCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneAdvanced breast cancerCDK4/6 inhibitorEndocrine therapyHormone receptor positiveHuman epidermal growth factor receptor 2 negative

Identifiers

PMID42426738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.